171 related articles for article (PubMed ID: 34872672)
21. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
22. Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.
Azzopardi M; Thomas R; Muruganandan S; Lam DC; Garske LA; Kwan BC; Rashid Ali MR; Nguyen PT; Yap E; Horwood FC; Ritchie AJ; Bint M; Tobin CL; Shrestha R; Piccolo F; De Chaneet CC; Creaney J; Newton RU; Hendrie D; Murray K; Read CA; Feller-Kopman D; Maskell NA; Lee YC
BMJ Open; 2016 Jul; 6(7):e011480. PubMed ID: 27381209
[TBL] [Abstract][Full Text] [Related]
23. Malignant pleural mesothelioma.
Klepetko W
Wien Klin Wochenschr; 2016 Sep; 128(17-18):609-10. PubMed ID: 27457871
[No Abstract] [Full Text] [Related]
24. Successful drainage of complex haemoserous malignant pleural effusion with a single modified low-dose intrapleural alteplase and dornase alfa.
Ng BH; Mohd Aminudin NH; Nasaruddin MZ; Abdul Rahaman JA
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33547099
[TBL] [Abstract][Full Text] [Related]
25. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.
Matsuzaki Y; Shibata K; Yoshioka M; Inoue M; Sekiya R; Onitsuka T; Iwamoto I; Koga Y
Ann Thorac Surg; 1995 Jan; 59(1):127-31. PubMed ID: 7818311
[TBL] [Abstract][Full Text] [Related]
26. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
27. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
28. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions.
Cantó A; Guijarro R; Arnau A; Galbis J; Martorell M; García Aguado R
Thorac Cardiovasc Surg; 1997 Feb; 45(1):16-9. PubMed ID: 9089969
[TBL] [Abstract][Full Text] [Related]
29. Malignant pleural fluid from mesothelioma has potent biological activities.
Cheah HM; Lansley SM; Varano Della Vergiliana JF; Tan AL; Thomas R; Leong SL; Creaney J; Lee YC
Respirology; 2017 Jan; 22(1):192-199. PubMed ID: 27560254
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolysis of loculated pleural effusion in malignant mesothelioma.
Balamugesh T; Christopher DJ; Rajesh T; Prince J
Singapore Med J; 2004 Dec; 45(12):594-5. PubMed ID: 15568123
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
Astoul P; Bertault-Peres P; Durand A; Catalin J; Vignal F; Boutin C
Cancer; 1994 Jan; 73(2):308-13. PubMed ID: 8293393
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-5-producing malignant pleural mesothelioma with eosinophilic pleural effusion.
Takeuchi E; Takahashi N; Morizumi S; Tamiya H; Matsuoka H; Kuroda N; Yorita K
Thorac Cancer; 2020 Oct; 11(10):3043-3046. PubMed ID: 32894005
[TBL] [Abstract][Full Text] [Related]
33. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis.
Ohta Y; Shimizu Y; Matsumoto I; Watanabe G
J Exp Clin Cancer Res; 2006 Mar; 25(1):15-9. PubMed ID: 16761613
[TBL] [Abstract][Full Text] [Related]
34. [Management of malignant pleural effusion].
Zalcman G; Lechapt E; Bergot E
Rev Prat; 2007 Mar; 57(5):513-23. PubMed ID: 17583136
[TBL] [Abstract][Full Text] [Related]
35. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
36. Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM; Alrifai D; Fennell DA
N Engl J Med; 2021 Sep; 385(13):1207-1218. PubMed ID: 34551230
[No Abstract] [Full Text] [Related]
37. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
38. Pleural effusions and pneumothorax: Beyond simple plumbing: Expert opinions on knowledge gaps and essential next steps.
Thomas R; Rahman NM; Maskell NA; Lee YCG
Respirology; 2020 Sep; 25(9):963-971. PubMed ID: 32613624
[TBL] [Abstract][Full Text] [Related]
39. The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.
Bibby AC; Halford P; De Fonseka D; Morley AJ; Smith S; Maskell NA
Ann Am Thorac Soc; 2019 Oct; 16(10):1273-1279. PubMed ID: 31189069
[No Abstract] [Full Text] [Related]
40. Updates in Staging and Management of Malignant Pleural Mesothelioma.
Wolf AS; Flores RM
Surg Oncol Clin N Am; 2020 Oct; 29(4):603-612. PubMed ID: 32883461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
